United Orthopedic Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From United Orthopedic Corporation
I-Mab sets commercial plans with Sinopharm for felzartamab in multiple myeloma. Legochem and Antengene team up on antibody-drug conjugates, Luoxin licenses respiratory drug from Marinomed.
Although the U.S. market for sports medicine products is dominated by conservative care products, new surgical techniques and products, including arthroscopy products and surgical implants, are fueling growth in the market, which is projected to reach almost $15.5 billion by 2018.
Although the US sports medicine market is dominated by conservative care treatments, new surgical techniques, arthroscopy products and surgical implants are fueling growth in the market, which is projected to reach almost $15.5 billion by 2018. Industry consolidation and dealmaking among orthopedic manufacturers has yielded several partnerships and M&As that have included a sports medicine element.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced October-November 2014.
- Services sold to health care facilities
- Consumables, Central Supplies
- Implantable Devices
- Other Names / Subsidiaries
- United Orthopedic Corporation USA